A Report on the Longevity Therapeutics Summit
The Longevity Therapeutics Summit focused more on the therapeutics that target ageing than on basic research or theory.
The Longevity Therapeutics Summit was held for the first time in San Francisco, California. The conference was organized by Hanson Wade with John Lewis as the program chair. It focused on senolytics to clear senescent cells, using big data and AI for finding new drugs (in silico testing), and delivery systems for therapeutics such as senolytics and TORC1 drugs.
The conference was a smorgasbord for cutting-edge research on longevity. As the name suggests, the focus of the event was more on the therapeutics to combat aging than the basic research and theory.
Ned David (CEO of Unity Biotechnology) opened the conference by presenting the latest research from the company on senolytics. These are drugs that remove senescent cells (\”zombies\”), which can secrete toxic chemicals which cause nearby cells to become senescent. Unity Biotechnology made headlines recently when it requested an extension for its clinical trials of its first in class senolytics to treat osteoarthritis. The preliminary Phase 1 results of the clinical trial were deemed safe, a significant step towards obtaining FDA approval. Full results are expected later this year or 2020.
Source:
https://www.leafscience.org/a-report-from-the-longevity-therapeutics-summit/
